Synergy Capital Managers announce investment in Darl

11 Dec 2015

Synergy Capital Managers is  pleased to announce the completion of an investment in Darl Pharmaceuticals Limited by Synergy Private Equity Fund LP (SPEF). Darl is a fast growing pharmaceutical integrated value chain business with presence from production to last mile.

Since inception in 2010, Darl has consciously evolved into a strategic player in the supply chain for production and distribution of own-manufactured and contract manufactured pharmaceutical products across Ghana. Darl is focused on building a best-in-class integrated pharmaceutical operation establishing a dominant position in the market.

The investment in Darl is the first by SPEF in Ghana and the fourth overall since its first close in September 2014. This investment will enable the company undertake the expansion of its business including increasing manufacturing capacity and distribution footprint nationally.

Mr. David Ado, promoter and CEO of Darl Pharmaceuticals commenting on the investment said “ We are delighted about the investment of Synergy Private Equity Fund in Darl. With our current expansion, we expect to more than quadruple revenue within a year and further entrench our position in the market. Our goal is to be the number one brand in the pharmaceutical industry, offering unique selling experience using a rich talent of human resource. We know we can achieve our goal and attract more resources to enable us enter the sub-region.

In Darl, the Manager believes it has found value managers with a proven capacity to grow business as they have built the company from start-up to its present position achieving commendable year-on-year growth in the process. We are convinced that the company has great potential to establish a market leading position in the pharmaceutical industry in Ghana.

According to Akintoye Akindele, Partner, Synergy Capital Managers “Darl is a very interesting opportunity for us. We find the founders very impressive and they show the commitment that is required to build this franchise into a leading pharmaceutical business not just in Ghana, but also across the region in the future. We are very excited to partner with them to build a world-class business”.

Ghana represents an important market for us and we continue to see very attractive opportunities across numerous industry sectors. We are working to complete a couple more investments in Ghana in the coming months.

« Back to Member News

Adeniyi Adenubi, Executive Director – Institutional Business and Investor Relations at @VFDGroup talks to us about… https://t.co/CQLOo5yOxx

@AVCA_Africa’s Institutional Investor Masterclass is only 2 weeks away! Don’t miss the opportunity to strengthen yo… https://t.co/nlSSehEfWl

2 more weeks until @AVCA_Africa’s Connect with @NLawGlobal! Join us on Monday, 2nd December at Shimmy Beach Club, C… https://t.co/a56yVNezEb

RT @ABANAngels: Happening NOW!! #AESIS2019 Research Roundtable with reps from @VC4Africa @Briter_bridges @DisruptAfrica @AVCA_Africa @baoba…

Join Sarah Shackleton and Shane Rogel on 11/12/19 as they introduce AVCA's Operational Due Dilligence guide - an in… https://t.co/xkbytmUE2Z

;